The fifth Covid-19 vaccine candidate has made its way into late-stage clinical trials in Western countries. Elizabeth Warren tells Elon Musk she's 'happy' to work with him on DOGE's goals to slash ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

Novavax stock more than doubled in response to a licensing deal with a big pharma partner. Sanofi will give Novavax $500 million up front to co-license and co-commercialize its COVID-19 vaccine. The ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators put a ...

There's another COVID-19 vaccine. This one was developed by the U.S. biotech company Novavax. It's almost 90% effective against the disease, but... Novavax Vaccine Effective, But Doesn't Work As Well ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...